Your browser doesn't support javascript.
MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes.
Lu, Dongchao; Chatterjee, Shambhabi; Xiao, Ke; Riedel, Isabelle; Wang, Yibin; Foo, Roger; Bär, Christian; Thum, Thomas.
  • Lu D; Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany; REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany.
  • Chatterjee S; Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany; REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany.
  • Xiao K; Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany.
  • Riedel I; Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany.
  • Wang Y; Department of Anesthesiology, Medicine and Physiology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
  • Foo R; Genome Institute of Singapore, Cardiovascular Research Institute, National University of Singapore, Centre for Translational Medicine, Singapore, Republic of Singapore.
  • Bär C; Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany; REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany. Electronic address: baer.christian@mh-hannover.de.
  • Thum T; Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany; REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany. Electronic address: thum.thomas@mh-hannover.de.
J Mol Cell Cardiol ; 148: 46-49, 2020 11.
Article in English | MEDLINE | ID: covidwho-741564
ABSTRACT
The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) as a public health emergency of international concern as more than 15 million cases were reported by 24th July 2020. Angiotensin-converting enzyme 2 (ACE2) is a COVID-19 entry receptor regulating host cell infection. A recent study reported that ACE2 is expressed in cardiomyocytes. In this study, we aimed to explore if there are microRNA (miRNA) molecules which target ACE2 and which may be exploited to regulate the SARS-CoV-2 receptor. Our data reveal that both Ace2 mRNA and Ace2 protein levels are inhibited by miR-200c in rat primary cardiomyocytes and importantly, in human iPSC-derived cardiomyocytes. We report the first miRNA candidate that can target ACE2 in cardiomyocytes and thus may be exploited as a preventive strategy to treat cardiovascular complications of COVID-19.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Myocytes, Cardiac / MicroRNAs / Angiotensin-Converting Enzyme 2 / COVID-19 / Myocardium Limits: Animals / Humans Language: English Journal: J Mol Cell Cardiol Year: 2020 Document Type: Article Affiliation country: J.yjmcc.2020.08.017

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Myocytes, Cardiac / MicroRNAs / Angiotensin-Converting Enzyme 2 / COVID-19 / Myocardium Limits: Animals / Humans Language: English Journal: J Mol Cell Cardiol Year: 2020 Document Type: Article Affiliation country: J.yjmcc.2020.08.017